Stocktoria
Esperion Therapeutics, Inc. ESPR
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2013-06-24
Esperion Therapeutics, Inc. statistics & valuation
Market cap$816.9M
P / S2.0×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | 15.0% | 16.4% | -133.7% | -237.8% | -289.0% |
| Net margin | -5.6% | -15.6% | -179.9% | -309.6% | -343.0% |
| FCF margin | -3.2% | -7.2% | -116.5% | -231.6% | -336.3% |
| Return on assets | -4.9% | -15.0% | -101.7% | -94.2% | -70.5% |
| Return on equity | 7.5% | 13.3% | 46.0% | 72.2% | 136.6% |
| Current ratio | 1.54 | 1.37 | 1.29 | 2.67 | 4.48 |
| Revenue growth | 21.3% | 185.7% | 54.1% | -3.8% | -65.5% |
Source: SEC EDGAR filings · CIK 0001434868 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.